Atricure, Inc. · NASDAQ:ATRC
Atricure — J.P. Morgan Healthcare Conference 2023
18 slides from Atricure's conference presentation, Jan 9, 2023
Slide 1: Creating a World Class Platform
Creating a World Class Platform JANUARY 2023 © 2023 AtriCure, Inc. All rights reserved. J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other thin
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures as supplemental financial metrics in t
Slide 4: Afib: A Serious Problem
Afib: A Serious Problem © 2023 AtriCure, Inc. All rights reserved. 4 8 Million2 Atrial Fibrillation (Afib) is an irregular heartbeat (or arrhythmia) that affects more than 37 million people worldwide.1 1 in 4 Adults Over 40 will develop Afib in their lifetime4 8 Million People estimated to have Afib
Slide 5: Afib: A Serious Problem
Afib: A Serious Problem © 2023 AtriCure, Inc. All rights reserved. 5 5x Higher Risk of Stroke5 46% Greater Risk of Mortality6 >5x Higher Risk of Heart Failure7 Afib is tied to higher risk of stroke, heart failure, dementia, and other health problems
Slide 6: AtriCure: Foundation for Success
Durable Growth Strong history of revenue growth and acceleration from multiple catalysts Expansion Developing addressable markets and expanding patient impact globally Innovation Continuous improvement, increasing pipeline AtriCure: Foundation for Success © 2023 AtriCure, Inc. All rights reserved. 6
Slide 7: Innovative and Expanding Product Portfolio
Innovative and Expanding Product Portfolio © 2023 AtriCure, Inc. All rights reserved. Ablation LAA Management EPI-SENSE® DEVICE ATRICLIP PRO•V® DEVICE ATRICLIP FLEX•V® DEVICE cryoICE® CRYOABLATION PROBE ISOLATOR® SYNERGY™ CLAMP ATRICLIP® FLEX DEVICE ATRICLIP PRO® DEVICE cryoSPHERE® CRYOABLATION PROB
Slide 8: Differentiated and Growing Clinical Evidence
Isolator® Synergy Ablation System approved by FDA for treatment of persistent or long-standing persistent Afib concomitant to open heart procedures CONVERGE IDE Trial: EPi-Sense® Guided Coagulation System approved by FDA for treatment of long-standing persistent Afib FROST Study: Pain Management in
Slide 9: Cardiac Surgery Opportunity (US)
~$900M Concomitant Open Procedures (Open Ablation/LAAM) Cardiac Surgery Opportunity (US) © 2023 AtriCure, Inc. All rights reserved. ~$500M annually Cardiac Surgery with pre-op Afib Estimated penetration <30% Market opportunity and penetration estimates based on internal estimates and research, as we
Slide 10: Hybrid Opportunity (US)
Hybrid Opportunity (US) © 2023 AtriCure, Inc. All rights reserved. >$2B and growing Long-standing Persistent Afib patients (untreated) Market size estimated at 5% penetration Market opportunity and penetration estimates based on internal estimates and research, as well as from publicly available inf
Slide 11: CONVERGE: Long-standing Persistent Afib Patient Analysis
66% 61% 37% 26% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 12 months 18 months Convergent Catheter Ablation • Superior outcomes with hybrid Convergent procedure when compared to endocardial catheter ablation alone in patients with drug refractory long- standing persistent Afib, with majority of pat
Slide 12: Pain Management Opportunity (US)
Pain Management Opportunity (US) © 2023 AtriCure, Inc. All rights reserved. ~$350M annually Thoracic Procedures Estimated penetration <15% Market opportunity and penetration estimates based on internal estimates and research, as well as from publicly available information. 12 ~$600M annually Sternot
Slide 13: Significant Global Market Opportunity
Significant Global Market Opportunity © 2023 AtriCure, Inc. All rights reserved. Dedicated sales and training expertise $5B+ Global Opportunity LOW PENETRATION IN EXISTING MARKETS EXPANSION OPPORTUNITIES IN FOCUS 13 Market opportunity and penetration estimates based on internal estimates and researc
Slide 14: Financial Results and 2023 Outlook
Financial Results and 2023 Outlook © 2023 AtriCure, Inc. All rights reserved. * 2022 is Revenue is preliminary and unaudited. 2022 Adjusted EBITDA based on 2022 guidance for a loss of approximately $4 million. ** 2023 Revenue based on midpoint of Revenue guidance range. 2023 Adjusted EBITDA based on
Slide 15: Commitment to Sustainability
Commitment to Sustainability © 2023 AtriCure, Inc. All rights reserved. 15 35th All Top 10 Heart Hospitals Use AtriCure Products US NEWS & WORLD REPORT BEST HOSPITALS: CARDIOLOGY AND HEART SURGERY 2022-23 >800 attendees Inaugural sustainability report published ESG NACD Diversity & Inclusion award r
Slide 16: Large Markets, Strong Portfolio, Bright Future
Large Markets Addressing an underserved and growing patient population Strong Portfolio Existing products and solutions driving consistent growth Bright Future Novel therapies supported by growing body of clinical evidence We are passionately focused on healing the lives of those affected by Afib an
Slide 17: Thank You!
Thank You! © 2023 AtriCure, Inc. All rights reserved.
Slide 18: References and Abbreviations
References and Abbreviations © 2023 AtriCure, Inc. All rights reserved. Note Reference 1 European Heart Journal – Quality of Care and Clinical Outcomes (2021) 7, 574-582 doi: 10.1093/ehjqcco/qcaa061 2 The American Journal of Cardiology (2013), 112: 1142-1147 3 Medical management estimate: Colilia, e